UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio

UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio

286521

UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio

The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K. clinical trial investigating ways of safely lowering the treatment burden of cystic fibrosis (CF), a top priority for patients and their healthcare teams. The randomized and open-label trial, called CF STORM, will enroll 764 CF patients across the U.K. on a stable treatment regimen with Kaftrio (by Vertex; sold as Trikafta in the U.S.),…

You must be logged in to read/download the full post.